Physician profile
Lauren E Choi
NPI 1699736132
$8,842.98
in general payments reported to CMS, 2019-2025
36 companies · $798 in 2025
The $798 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,190 · 2020: $1,152 · 2021: $582 · 2022: $812 · 2023: $1,109 · 2024: $1,201 · 2025: $798.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,107.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $1,573.76 | 2019-2025 | Mounjaro, Trulicity, Zepbound |
| Dexcom, INC. | $1,183.65 | 2021-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $1,166.78 | 2019-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $1,092.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $791.62 | 2019-2023 | |
| Amgen INC. | $457.97 | 2019-2020 | |
| Radius Health, INC. | $349.35 | 2019-2023 | Tymlos |
| Merck Sharp & Dohme LLC | $228.22 | 2019-2021 | |
| Abbvie INC. | $202.54 | 2019-2023 | Vraylar |
| Corcept Therapeutics | $199.06 | 2019-2023 | Korlym |
| Astrazeneca Pharmaceuticals LP | $194.55 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $150.56 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Lifescan, INC. | $115.29 | 2019-2020 | |
| Ibsa Pharma INC. | $101.95 | 2019-2020 | |
| Insulet Corporation | $96.26 | 2019-2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $95.61 | 2019 | |
| Medtronic, INC. | $92.85 | 2021 | |
| Becton, Dickinson and Company | $84.86 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $80.72 | 2019-2023 | Jardiance |
| Glaxosmithkline, LLC. | $69.10 | 2022-2023 | Trelegy Ellipta |
| Xeris Pharmaceuticals, INC. | $56.31 | 2021-2024 | Keveyis |
| Amryt Pharma Holdings LTD | $55.35 | 2022 | |
| Zealand Pharma US, INC. | $54.52 | 2021 | |
| Medtronic Minimed, INC. | $54.08 | 2019-2020 | |
| Valeritas, INC. | $49.20 | 2019 | |
| Beta Bionics, INC. | $42.27 | 2023 | Ilet Bionic Pancreas |
| Janssen Pharmaceuticals, INC | $42.14 | 2019 | |
| Amneal Pharmaceuticals LLC | $27.33 | 2019 | |
| Horizon Therapeutics Plc | $20.60 | 2019 | |
| Mannkind Corporation | $20.42 | 2023 | Afrezza |
| Aytu Biopharma, INC. | $19.44 | 2019 | |
| Pfizer INC. | $19.43 | 2023 | |
| Impel Pharmaceuticals INC. | $15.22 | 2022 | |
| Vistapharm, INC. | $13.61 | 2021 | |
| Amarin Pharma, INC. | $13.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $12.62 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lauren Choi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.